. 2022 Oct 27;2022:5844846. doi: 10.1155/2022/5844846

Table 2.

Clinical information of TCGA and three independent cohorts.

Item	TCGA (n = 363)	GSE15459 (n = 192)	GSE26253 (n = 432)	GSE 84437 (n = 433)
Age (years; mean ± sd)	64.98 ± 10.55	64.37 ± 13.24		60.06 ± 11.58
Gender (female/male)	125/238	67/125		137/296
Race (Asian/Black or African American/White/not reported)	84/12/236/31
Time (days; median)	463	574	1735	2087
Status (0/1)^a	219/144	97/95	255/177	224/209
Stage (I/II/III/IV/-)	46/118/161/28/10	31/29/72/60/0	68/167/130/67/0
Pathologic T stage (T1/T2/T3/T4)	18/72/168/105			11/38/92/292
Pathologic N stage (N0/N1/N2/N3/NX/-)	112/95/72/76/6/2			80/188/132/33/0/0
Pathologic M stage (M0/M1/MX)	327/19/17

^aStatus 1 means reaching the endpoint. For TCGA and GSE15459, the endpoint is OS. For GSE26253, the endpoint is DFS. For GSE84437, the endpoint is the response of the fourfold increase from the baseline of the heterotopic tumor size.